Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.

Also called NCT02960204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 263 participants (enrolled count) (from the registry)
Sponsor
Histogen (from the registry)
Registry
  • NCT NCT02960204
Main results
  • Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension Journal of hepatology, 2020-05 DOI, PubMed 31870950

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02960204. Randomized; triple masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-10-02 (actual). Results posted on 2022-01-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension
Acronym
ENCORE-PH
Condition
Cirrhosis
Condition
Portal Hypertension
Condition
Non-alcoholic Steatohepatitis
Intervention (Drug)
Emricasan
Intervention (Drug)
Placebo
Lead sponsor
Histogen (class: industry)

Record details

Record id
cardio:ct-nct02960204
Content hash
580cca8b994119a868336430f69c699dcdf1539366f06ec3b25c97e1f11a0431